The reversal created by massive merger news erupting from an extreme oversold zone

Reviewing Prediction vs. Actual Result

Far exceeding the expected 12.5% return, the actual result led to a massive surge of 336.4%. At the time of entry, the strategy targeting bargain-hunting near the $1.41 support level—amid an oversold condition with an RSI of 25.4 and a sharp -21.4% decline—proved effective. However, we note that the upside potential was not fully captured because the ripple effect of the powerful positive catalyst—specifically, the all-stock merger and acquisition between Aethlon Medical and North Immunology—was estimated too conservatively.

What to Watch in the Next Analysis

Through this trade, I once again realized the explosive impact that major M&A news coinciding with an oversold condition can have on stock prices. In future trades, when technical indicators point to oversold levels and coincide with powerful ad hoc disclosure events (such as 8-Ks), rather than mechanically liquidating at a simple target price, I will apply a complementary measure to flexibly raise the profit-taking threshold in accordance with the weight of the positive catalyst.